标签归档：pkc

Darovasertib(Synonyms: LXS196; IDE196)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Darovasertib (Synonyms: LXS196; IDE196) 纯度: 99.68%

Darovasertib (LXS196) 是有效的、选择性的和具有口服活性的蛋白激酶C (PKC) 抑制剂，对 PKCα、PKCθ 和 GSK3β 的 IC50 值分别为 1.9 nM、0.4 nM 和 3.1 μM。Darovasertib 有潜力用于葡萄膜黑素瘤的研究。

Darovasertib(Synonyms: LXS196; IDE196)

Darovasertib Chemical Structure

CAS No. : 1874276-76-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1611 In-stock
2 mg ￥800 In-stock
5 mg ￥1550 In-stock
10 mg ￥2350 In-stock
25 mg ￥4090 In-stock
50 mg ￥6100 In-stock
100 mg ￥9200 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Darovasertib 相关产品

•相关化合物库:

  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Epigenetics Compound Library
  • Kinase Inhibitor Library
  • TGF-beta/Smad Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Cytoskeleton Compound Library
  • Orally Active Compound Library

生物活性

Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research[1][2].

IC50 & Target[2]

PKCα

1.9 nM (IC50)

PKCθ

0.4 nM (IC50)

GSK3β

3.1 μM (IC50)

体外研究
(In Vitro)

Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Darovasertib (LXS196; compound 9) (15, 30, 75, 150 mg/kg, P.O., mice) shows improved efficacy (regression) in a 92.1 GNAQ uveal melanoma xenograft model in a dose-dependently manner[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice implanted with 92.1 GNAQ mutant uveal melanoma cells[2].
Dosage: 15, 30, 75, 150 mg/kg
Administration: P.O. (bid) for 35 days
Result: Dose-dependently suppressed the tumor growth.

Clinical Trial

分子量

472.47

Formula

C22H23F3N8O
CAS 号

1874276-76-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 25 mg/mL (52.91 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1165 mL 10.5827 mL 21.1654 mL
5 mM 0.4233 mL 2.1165 mL 4.2331 mL
10 mM 0.2117 mL 1.0583 mL 2.1165 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.29 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.29 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.29 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

  • 4.

    请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 1.67 mg/mL (3.53 mM); Clear solution

  • 5.

    请依序添加每种溶剂： 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.67 mg/mL (3.53 mM); Clear solution

  • 6.

    请依序添加每种溶剂： 1% DMSO    99% saline

    Solubility: 0.33 mg/mL (0.70 mM); Suspended solution; Need ultrasonic

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Protein Kinase C Inhibitor LXS196

    [2]. US20180179181.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制epsilon-V1-2, epsilon-PKC Inhibitor 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 epsilon-V1-2, epsilon-PKC Inhibitor
编码
别名 epsilon-V1-2, epsilon-PKC Inhibitor
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） EAVSLKPT
序列（三字母缩写） H-Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr-OH (trifluoroacetate salt)
基本描述 This glycopeptide is 117 to 131 fragment of erythropoietin (Epo) glycosylated at Ser126. Human erythropoietin is a principle regulator of the hematopoiesis and it stimulates the differentiation of erythroid progenitor cells into mature erythrocytes.
溶解度
分子量 844
化学式 C37H65N9O13
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents epsilon-V1-2, epsilon-PKC Inhibitor 编码
Figures epsilon-V1-2, epsilon-PKC Inhibitor 编码
Reference Lamy, C. et al. Tetrahedron Lett 46, 6177 (2007) Brandman, R. et al. J. Biol. Chem. 282, 4113 (2007)
C端
N端
化学桥

Midostaurin-d5(Synonyms: PKC412-d5; CGP 41251-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Midostaurin-d5 (Synonyms: PKC412-d5; CGP 41251-d5)

Midostaurin-D5 (PKC412-D5) 是 Midostaurin 的氘代化合物。Midostaurin 是一种多靶点蛋白激酶抑制剂，抑制 PKCα/β/γ，Syk，Flk-1，Akt，PKA，c-Kit，c-Fgr，c-Src，FLT3，PDFRβ 和 VEGFR1/2 的活性，IC50 值为 22-500 nM。

Midostaurin-d5(Synonyms: PKC412-d5; CGP 41251-d5)

Midostaurin-d5 Chemical Structure

规格 价格 是否有货
1 mg ￥5200 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Midostaurin-D5 (PKC412-D5) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

分子量

575.67

Formula

C35H25D5N4O4
中文名称

米哚妥林 d5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Fabbro D, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999 May-Jun;82(2-3):293-301.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

O-Desmethyl Midostaurin-d5 (Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl PKC412-d5 (CGP62221-d5) 是 O-Desmethyl PKC412 的氘代物。O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) 是 Midostaurin (HY-10230) 的活性代谢物，通过细胞色素 P450 肝酶代谢产生，可以作为 Midostaurin 在体内代谢的指标之一。

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl Midostaurin-d5 Chemical Structure

规格 价格 是否有货
1 mg ￥10500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

O-Desmethyl PKC412-d5 (CGP62221-d5) is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].

IC50 & Target

IC50: active metabolite of Midostaurin[1]
分子量

561.64

Formula

C34H23D5N4O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Levis M, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-83.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

O-Desmethyl Midostaurin-d5 (Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl PKC412-d5 (CGP62221-d5) 是 O-Desmethyl PKC412 的氘代物。O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) 是 Midostaurin (HY-10230) 的活性代谢物，通过细胞色素 P450 肝酶代谢产生，可以作为 Midostaurin 在体内代谢的指标之一。

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl Midostaurin-d5 Chemical Structure

规格 价格 是否有货
1 mg ￥10500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

O-Desmethyl PKC412-d5 (CGP62221-d5) is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].

IC50 & Target

IC50: active metabolite of Midostaurin[1]
分子量

561.64

Formula

C34H23D5N4O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Levis M, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-83.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

O-Desmethyl Midostaurin-d5 (Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl PKC412-d5 (CGP62221-d5) 是 O-Desmethyl PKC412 的氘代物。O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) 是 Midostaurin (HY-10230) 的活性代谢物，通过细胞色素 P450 肝酶代谢产生，可以作为 Midostaurin 在体内代谢的指标之一。

O-Desmethyl Midostaurin-d5(Synonyms: CGP62221-d5; O-Desmethyl PKC412-d5)

O-Desmethyl Midostaurin-d5 Chemical Structure

规格 价格 是否有货
1 mg ￥10500 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

O-Desmethyl PKC412-d5 (CGP62221-d5) is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].

IC50 & Target

IC50: active metabolite of Midostaurin[1]
分子量

561.64

Formula

C34H23D5N4O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Levis M, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-83.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PS315

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PS315 

PS315 是 PS48 (HY-15967) 的衍生物，是一种变构性 PKC 抑制剂，可以与 aPKC 的 PIF 口袋结合并诱导活性位点残基 Lys111 置换。PS315 抑制 PKCζ (IC50=10 μM) 和 PKCη (IC50=30 μM) 的全长和催化结构域构建体。PS315 具有抗癌活性。

PS315

PS315 Chemical Structure

CAS No. : 1221964-50-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity[1].

IC50 & Target[1]

PKCζ

10 μM (IC50)

PKCη

30 μM (IC50)

体外研究
(In Vitro)

Preincubation of U937 cells with 5 μM PS315 inhibits TNF-α induced NF-κB activation by 74%, whereas complete inhibition is observed with 10 μM PS315[1].
The small allosteric inhibitor PS315 and the N-terminal region of aPKC both act directly on the PIF-pocket on-off switch. PS315, binding at the PIF-pocket, induces a displacement of the active site residue Lys111, thereby inhibiting the activity of aPKCs by allosterically affecting the catalytic mechanism of the kinase[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

362.85

Formula

C23H19ClO2
CAS 号

1221964-50-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhang H, et al. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. Chem Biol. 2014 Jun 19;21(6):754-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PS315

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PS315 

PS315 是 PS48 (HY-15967) 的衍生物，是一种变构性 PKC 抑制剂，可以与 aPKC 的 PIF 口袋结合并诱导活性位点残基 Lys111 置换。PS315 抑制 PKCζ (IC50=10 μM) 和 PKCη (IC50=30 μM) 的全长和催化结构域构建体。PS315 具有抗癌活性。

PS315

PS315 Chemical Structure

CAS No. : 1221964-50-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity[1].

IC50 & Target[1]

PKCζ

10 μM (IC50)

PKCη

30 μM (IC50)

体外研究
(In Vitro)

Preincubation of U937 cells with 5 μM PS315 inhibits TNF-α induced NF-κB activation by 74%, whereas complete inhibition is observed with 10 μM PS315[1].
The small allosteric inhibitor PS315 and the N-terminal region of aPKC both act directly on the PIF-pocket on-off switch. PS315, binding at the PIF-pocket, induces a displacement of the active site residue Lys111, thereby inhibiting the activity of aPKCs by allosterically affecting the catalytic mechanism of the kinase[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

362.85

Formula

C23H19ClO2
CAS 号

1221964-50-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhang H, et al. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. Chem Biol. 2014 Jun 19;21(6):754-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PS315

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PS315 

PS315 是 PS48 (HY-15967) 的衍生物，是一种变构性 PKC 抑制剂，可以与 aPKC 的 PIF 口袋结合并诱导活性位点残基 Lys111 置换。PS315 抑制 PKCζ (IC50=10 μM) 和 PKCη (IC50=30 μM) 的全长和催化结构域构建体。PS315 具有抗癌活性。

PS315

PS315 Chemical Structure

CAS No. : 1221964-50-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity[1].

IC50 & Target[1]

PKCζ

10 μM (IC50)

PKCη

30 μM (IC50)

体外研究
(In Vitro)

Preincubation of U937 cells with 5 μM PS315 inhibits TNF-α induced NF-κB activation by 74%, whereas complete inhibition is observed with 10 μM PS315[1].
The small allosteric inhibitor PS315 and the N-terminal region of aPKC both act directly on the PIF-pocket on-off switch. PS315, binding at the PIF-pocket, induces a displacement of the active site residue Lys111, thereby inhibiting the activity of aPKCs by allosterically affecting the catalytic mechanism of the kinase[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

362.85

Formula

C23H19ClO2
CAS 号

1221964-50-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhang H, et al. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. Chem Biol. 2014 Jun 19;21(6):754-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mezerein (Synonyms: 密执毒素；欧瑞香脂；)

Mezerein 是一种 PKC 激活剂，具有抗白血病特性。 Mezerein 抑制表达 PKC alpha (IC50=1190 nM)、PKC beta1 (IC50=908 nM) 和 PKC delta (IC50=141 nM) 的酵母生长，但不抑制表达 PKC 的酵母生长。

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

Mezerein Chemical Structure

CAS No. : 34807-41-5

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Mezerein is a PKC activator that exhibits antileukemic properties. Mezerein inhibits the growth of yeast expressing PKC alpha (IC50=1190 nM), PKC beta1 (IC50=908 nM), and PKC delta (IC50=141 nM) but not of yeast expressing PKC[1][2].

体外研究
(In Vitro)

Mezerein is an antileukemic principle isolated from Daphne mezereum L[2].
Mezerein (50 ng/mL; 72 hours) potently inhibit tumorigenic murine macrophage cell line M5076 cellular proliferation[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[3]

Cell Line: M5076 cells
Concentration: 50 ng/mL
Incubation Time: 72 hours
Result: Inhibited cellular proliferation (by greater than 90%).

体内研究
(In Vivo)

Mezerein exhibits antileukemic activity against the P-388 lymphocytic leukemia in mice. Mezerein (50 μg/kg) shows significant inhibitory activity against the P-388 and L-1210 leukemias in mice[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.70

Formula

C38H38O10
CAS 号

34807-41-5
中文名称

密执毒素；欧瑞香脂；
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. L Saraiva, et al. Differential activation by daphnetoxin and mezerein of PKC-isotypes alpha, beta I, delta and zeta. Planta Med. 2001 Dec;67(9):787-90.

    [2]. S M Kupchan,et al.Mezerein: antileukemic principle isolated from Daphne mezereum L. Science. 1975 Feb 21;187(4177):652-3.

    [3]. N T Goode, et al. Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line. Cancer Res. 1990 Mar 15;50(6):1828-33.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mezerein (Synonyms: 密执毒素；欧瑞香脂；)

Mezerein 是一种 PKC 激活剂，具有抗白血病特性。 Mezerein 抑制表达 PKC alpha (IC50=1190 nM)、PKC beta1 (IC50=908 nM) 和 PKC delta (IC50=141 nM) 的酵母生长，但不抑制表达 PKC 的酵母生长。

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

Mezerein Chemical Structure

CAS No. : 34807-41-5

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Mezerein is a PKC activator that exhibits antileukemic properties. Mezerein inhibits the growth of yeast expressing PKC alpha (IC50=1190 nM), PKC beta1 (IC50=908 nM), and PKC delta (IC50=141 nM) but not of yeast expressing PKC[1][2].

体外研究
(In Vitro)

Mezerein is an antileukemic principle isolated from Daphne mezereum L[2].
Mezerein (50 ng/mL; 72 hours) potently inhibit tumorigenic murine macrophage cell line M5076 cellular proliferation[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[3]

Cell Line: M5076 cells
Concentration: 50 ng/mL
Incubation Time: 72 hours
Result: Inhibited cellular proliferation (by greater than 90%).

体内研究
(In Vivo)

Mezerein exhibits antileukemic activity against the P-388 lymphocytic leukemia in mice. Mezerein (50 μg/kg) shows significant inhibitory activity against the P-388 and L-1210 leukemias in mice[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.70

Formula

C38H38O10
CAS 号

34807-41-5
中文名称

密执毒素；欧瑞香脂；
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. L Saraiva, et al. Differential activation by daphnetoxin and mezerein of PKC-isotypes alpha, beta I, delta and zeta. Planta Med. 2001 Dec;67(9):787-90.

    [2]. S M Kupchan,et al.Mezerein: antileukemic principle isolated from Daphne mezereum L. Science. 1975 Feb 21;187(4177):652-3.

    [3]. N T Goode, et al. Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line. Cancer Res. 1990 Mar 15;50(6):1828-33.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mezerein (Synonyms: 密执毒素；欧瑞香脂；)

Mezerein 是一种 PKC 激活剂，具有抗白血病特性。 Mezerein 抑制表达 PKC alpha (IC50=1190 nM)、PKC beta1 (IC50=908 nM) 和 PKC delta (IC50=141 nM) 的酵母生长，但不抑制表达 PKC 的酵母生长。

Mezerein(Synonyms: 密执毒素；欧瑞香脂；)

Mezerein Chemical Structure

CAS No. : 34807-41-5

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Mezerein is a PKC activator that exhibits antileukemic properties. Mezerein inhibits the growth of yeast expressing PKC alpha (IC50=1190 nM), PKC beta1 (IC50=908 nM), and PKC delta (IC50=141 nM) but not of yeast expressing PKC[1][2].

体外研究
(In Vitro)

Mezerein is an antileukemic principle isolated from Daphne mezereum L[2].
Mezerein (50 ng/mL; 72 hours) potently inhibit tumorigenic murine macrophage cell line M5076 cellular proliferation[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[3]

Cell Line: M5076 cells
Concentration: 50 ng/mL
Incubation Time: 72 hours
Result: Inhibited cellular proliferation (by greater than 90%).

体内研究
(In Vivo)

Mezerein exhibits antileukemic activity against the P-388 lymphocytic leukemia in mice. Mezerein (50 μg/kg) shows significant inhibitory activity against the P-388 and L-1210 leukemias in mice[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

654.70

Formula

C38H38O10
CAS 号

34807-41-5
中文名称

密执毒素；欧瑞香脂；
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. L Saraiva, et al. Differential activation by daphnetoxin and mezerein of PKC-isotypes alpha, beta I, delta and zeta. Planta Med. 2001 Dec;67(9):787-90.

    [2]. S M Kupchan,et al.Mezerein: antileukemic principle isolated from Daphne mezereum L. Science. 1975 Feb 21;187(4177):652-3.

    [3]. N T Goode, et al. Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line. Cancer Res. 1990 Mar 15;50(6):1828-33.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PKCiota-IN-2

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PKCiota-IN-2 

PKCiota-IN-2 是一种有效的 PKCiota (PKC-ι) 抑制剂，IC50 为 2.8 nM。PKCiota-IN-2 还抑制 PKC-α 和 PKC-ε，IC50 分别为 71 nM 和 350 nM。

PKCiota-IN-2

PKCiota-IN-2 Chemical Structure

CAS No. : 2230055-52-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PKCiota-IN-2 is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively[1].

IC50 & Target[1]

PKCι

2.8 nM (IC50)

PKCα

71 nM (IC50)

PKCε

350 nM (IC50)

分子量

395.46

Formula

C24H21N5O
CAS 号

2230055-52-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Jacek Kwiatkowski, et al. Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors. J Med Chem. 2018 May 24;61(10):4386-4396.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制PKC-epsilon pseudosubstrate derived peptide 编码 [120253-69-2]

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 PKC-epsilon pseudosubstrate derived peptide
编码 [120253-69-2]
别名 PKC-epsilon pseudosubstrate derived peptide
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） ERMRPRKRQGSVRRRV
序列（三字母缩写） Glu-Arg-Met-Arg-Pro-Arg-Lys-Arg-Gln-Gly-Ser-Val-Arg-Arg-Arg-Val
基本描述
溶解度
分子量 2067.47
化学式 C83H155N39O21S
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents PKC-epsilon pseudosubstrate derived peptide 编码 [120253-69-2]
Figures PKC-epsilon pseudosubstrate derived peptide 编码 [120253-69-2]
Reference
C端
N端
化学桥

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(-)-Indolactam V-d8 (Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 (Indolactam V-d8) 是 (-)-Indolactam V 的氘代物。(-)-Indolactam V 是 PKC 的激活剂，对 η-CRD2 (PKCη 代替肽)，γ-CRD2 (PKCγ 代替肽) 的 Ki 值分别为 3.36 nM 和 1.03 μM，对 PKC C1A 和 C1B 结构域的 Kd 值分别为 5.5 nM (η-C1B)，7.7 nM (ε-C1

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

(-)-Indolactam V-d8 (Indolactam V-d8) is the deuterium labeled (-)-Indolactam V. (-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

309.43

Formula

C17H15D8N3O2
中文名称

吲哚内酰胺 V d8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Nakagawa Y, et al. Synthesis and biological activities of indolactone-V, the lactone analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem. 1997 Aug;61(8):1415-7.

    [3]. Masuda A, et al. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem. 2002 Jul;66(7):1615-7.

    [4]. Chen S, et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. 2009 Apr;5(4):258-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(-)-Indolactam V-d8 (Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 (Indolactam V-d8) 是 (-)-Indolactam V 的氘代物。(-)-Indolactam V 是 PKC 的激活剂，对 η-CRD2 (PKCη 代替肽)，γ-CRD2 (PKCγ 代替肽) 的 Ki 值分别为 3.36 nM 和 1.03 μM，对 PKC C1A 和 C1B 结构域的 Kd 值分别为 5.5 nM (η-C1B)，7.7 nM (ε-C1

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

(-)-Indolactam V-d8 (Indolactam V-d8) is the deuterium labeled (-)-Indolactam V. (-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

309.43

Formula

C17H15D8N3O2
中文名称

吲哚内酰胺 V d8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Nakagawa Y, et al. Synthesis and biological activities of indolactone-V, the lactone analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem. 1997 Aug;61(8):1415-7.

    [3]. Masuda A, et al. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem. 2002 Jul;66(7):1615-7.

    [4]. Chen S, et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. 2009 Apr;5(4):258-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(-)-Indolactam V-d8 (Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 (Indolactam V-d8) 是 (-)-Indolactam V 的氘代物。(-)-Indolactam V 是 PKC 的激活剂，对 η-CRD2 (PKCη 代替肽)，γ-CRD2 (PKCγ 代替肽) 的 Ki 值分别为 3.36 nM 和 1.03 μM，对 PKC C1A 和 C1B 结构域的 Kd 值分别为 5.5 nM (η-C1B)，7.7 nM (ε-C1

(-)-Indolactam V-d8(Synonyms: Indolactam V-d8)

(-)-Indolactam V-d8 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

(-)-Indolactam V-d8 (Indolactam V-d8) is the deuterium labeled (-)-Indolactam V. (-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

309.43

Formula

C17H15D8N3O2
中文名称

吲哚内酰胺 V d8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Nakagawa Y, et al. Synthesis and biological activities of indolactone-V, the lactone analogue of the tumor promoter (-)-indolactam-V. Biosci Biotechnol Biochem. 1997 Aug;61(8):1415-7.

    [3]. Masuda A, et al. Binding selectivity of conformationally restricted analogues of (-)-indolactam-V to the C1 domains of protein kinase C isozymes. Biosci Biotechnol Biochem. 2002 Jul;66(7):1615-7.

    [4]. Chen S, et al. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol. 2009 Apr;5(4):258-65.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Aurora A/PKC-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aurora A/PKC-IN-1 

Aurora A/PKC-IN-1 (Compound 2e) 是一种有效的 Aurora A (AurA) 和PKC (α, β1, β2, θ) 双效抑制剂，对 AurA 和 PKCα 分别具有 6.9 nM 和 16.9 nM。Aurora A/PKC-IN-1对乳腺癌细胞具有抗增殖和抗转移活性。

Aurora A/PKC-IN-1

Aurora A/PKC-IN-1 Chemical Structure

CAS No. : 2143100-98-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity[1].

IC50 & Target[1]

Aurora A

6.9 nM (IC50)

PKCα

16.9 nM (IC50)

分子量

464.24

Formula

C16H14N6OSe2
CAS 号

2143100-98-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Bijian K, et al. Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. J Med Chem. 2022;65(4):3134-3150.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Aurora A/PKC-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aurora A/PKC-IN-1 

Aurora A/PKC-IN-1 (Compound 2e) 是一种有效的 Aurora A (AurA) 和PKC (α, β1, β2, θ) 双效抑制剂，对 AurA 和 PKCα 分别具有 6.9 nM 和 16.9 nM。Aurora A/PKC-IN-1对乳腺癌细胞具有抗增殖和抗转移活性。

Aurora A/PKC-IN-1

Aurora A/PKC-IN-1 Chemical Structure

CAS No. : 2143100-98-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity[1].

IC50 & Target[1]

Aurora A

6.9 nM (IC50)

PKCα

16.9 nM (IC50)

分子量

464.24

Formula

C16H14N6OSe2
CAS 号

2143100-98-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Bijian K, et al. Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. J Med Chem. 2022;65(4):3134-3150.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Aurora A/PKC-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aurora A/PKC-IN-1 

Aurora A/PKC-IN-1 (Compound 2e) 是一种有效的 Aurora A (AurA) 和PKC (α, β1, β2, θ) 双效抑制剂，对 AurA 和 PKCα 分别具有 6.9 nM 和 16.9 nM。Aurora A/PKC-IN-1对乳腺癌细胞具有抗增殖和抗转移活性。

Aurora A/PKC-IN-1

Aurora A/PKC-IN-1 Chemical Structure

CAS No. : 2143100-98-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity[1].

IC50 & Target[1]

Aurora A

6.9 nM (IC50)

PKCα

16.9 nM (IC50)

分子量

464.24

Formula

C16H14N6OSe2
CAS 号

2143100-98-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Bijian K, et al. Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. J Med Chem. 2022;65(4):3134-3150.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务